Methotrexat Accord (Methotrexate)

Methotrexate is a folate antagonist that competitively inhibits dihydrofolate reductase, an enzyme essential for converting folic acid to its active form. This inhibition reduces the synthesis of nucleotides needed for DNA, RNA and protein production, thereby limiting the proliferation of rapidly dividing cells such as cancer cells and activated immune cells.

The dose of Methotrexat Accord is individualized by the prescribing healthcare professional based on the specific indication, disease severity, patient weight, renal and hepatic function, and other clinical factors. No fixed dosing regimen is provided here; the prescriber will set the appropriate dose and schedule.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and embryotoxicity. Women of child‑bearing potential must use effective contraception. Breastfeeding is not recommended while on methotrexate, as the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Methotrexat Accord. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexate is a small‑molecule antimetabolite that directly inhibits folate metabolism, whereas many biologic agents target specific cytokines or cell surface receptors. Compared with newer biologics, methotrexate is generally less expensive and has a well‑established safety profile, but it may be less selective and can require monitoring for organ toxicity.

Methotrexat Accord should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

Methotrexat Accord is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular or intrathecal routes, depending on the clinical indication and prescribing information. Administration is performed by qualified healthcare professionals in a controlled setting, following aseptic technique and appropriate dosing guidelines.

Serious adverse events include severe liver toxicity or fibrosis, pulmonary fibrosis or interstitial pneumonitis, and life‑threatening infections due to bone‑marrow suppression. Patients should be monitored regularly for liver enzymes, respiratory symptoms and blood counts, and any signs of severe toxicity should prompt immediate medical evaluation.

Methotrexate is contraindicated in patients with known hypersensitivity to the drug, severe renal or hepatic impairment, active infections, and in women who are pregnant or planning to become pregnant. Caution is also advised for individuals with pre‑existing blood dyscrasias or those receiving other myelosuppressive therapies.